Clinical and pathological absence of cardiotoxicity after liposomal doxorubicin

被引：16

作者：

Jones, RL

Berry, GJ

Rubens, RD

Miles, DW

机构：

[1] Royal Marsden Hosp, Dept Med, London SW3 6JJ, England

[2] Stanford Univ, Med Ctr, Stanford, CA 94305 USA

[3] Guys Hosp, London SE1 9RT, England

来源：

LANCET ONCOLOGY | 2004年 / 5卷 / 09期

关键词：

D O I：

10.1016/S1470-2045(04)01570-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

[No abstract available]

引用

页码：575 / 577

页数：3

共 10 条

[1]

Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma [J].

Harris, L ;

Batist, G ;

Belt, R ;

Rovira, D ;

Navari, R ;

Azarnia, N ;

Welles, K ;

Winer, E .

CANCER, 2002, 94 (01) :25-36

[2]

Mlineritsch B, 2001, BREAST CANCER RES TR, V69, P287

[3]

Safra T, 2003, ONCOLOGIST, V8, P17

[4]

Pegylated liposomal doxorubicin (doxil):: Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2 [J].

Safra, T ;

Muggia, F ;

Jeffers, S ;

Tsao-Wei, DD ;

Groshen, S ;

Lyass, O ;

Henderson, R ;

Berry, G ;

Gabizon, A .

ANNALS OF ONCOLOGY, 2000, 11 (08) :1029-1033

[5]

Doxorubicin-induced cardiomyopathy [J].

Singal, PK ;

Iliskovic, N .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (13) :900-905

[6]

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. [J].

Slamon, DJ ;

Leyland-Jones, B ;

Shak, S ;

Fuchs, H ;

Paton, V ;

Bajamonde, A ;

Fleming, T ;

Eiermann, W ;

Wolter, J ;

Pegram, M ;

Baselga, J ;

Norton, L .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (11) :783-792

[7]

THEODOULOU M, 2002, P AN M AM SOC CLIN, V21, P55

[8]

Trigo J, 2003, BREAST CANCER RES TR, V82, pS83

[9]

Wigler N, 2002, P AM SOC CLIN ONCOL, V21

[10]

Working PK, 1999, J PHARMACOL EXP THER, V289, P1128

← 1 →